The mental healthcare system is in desperate need of innovation.
By combining the growing potential of MDMA with digital therapeutics we aim to deliver safe, scalable psychotherapy to all those who need it — wherever and whenever they need it.
An atai Life Sciences company
EmpathBio is a biotech company dedicated to developing 3,4-Methylenedioxymethamphetamine derivatives in conjunction with digital therapeutics to deliver efficient, scalable treatments to patients on their own terms.
While MDMA-assisted psychotherapy holds great promise for the treatment of PTSD, refinement of MDMA's entactogenic pharmacology could provide for a greater therapeutic index. We want to ensure that entactogen-assisted psychotherapy is available to all struggling with PTSD.
- Glenn Short
, CEO, EmpathBio
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
NEW YORK and BERLIN, Nov. 10, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported financial results for the quarter ended September 30, 2022 and provided a business update.
November 10, 2022
ATAI Launches Subsidiary To Develop MDMA Derivatives
Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications.
August 24, 2020
From ‘party drug’ to PTSD treatment: ATAI launches EmpathBio to develop MDMA-based therapy
Treatment for post-traumatic stress disorder (PTSD) varies from patient to patient and can combine different kinds of therapy and drugs, including anti-anxiety meds and antidepressants. Problem is, the only drugs approved for PTSD don’t work for everyone, and even when they do, they don’t work perfectly and come with side effects.
August 24, 2020